<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1845">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04425629</url>
  </required_header>
  <id_info>
    <org_study_id>R10933-10987-COV-2067</org_study_id>
    <secondary_id>2020-003690-21</secondary_id>
    <nct_id>NCT04425629</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19</brief_title>
  <official_title>A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1&#xD;
&#xD;
        -  To evaluate the safety and tolerability of REGN10933+REGN10987 compared to placebo&#xD;
&#xD;
        -  To evaluate the virologic efficacy of REGN10933+REGN10987 compared to placebo in&#xD;
           reducing viral load of SARS-CoV-2&#xD;
&#xD;
      Phase 2 • To evaluate the virologic efficacy of REGN10933+REGN10987 compared to placebo in&#xD;
      reducing viral load of SARS-CoV-2&#xD;
&#xD;
      Phase 3&#xD;
&#xD;
        -  Cohort 1 (≥18 Years Old, Not Pregnant at Randomization)&#xD;
&#xD;
           • To evaluate the clinical efficacy of REGN10933+REGN10987 compared to placebo, using&#xD;
           the composite measure of COVID-19-related medically-attended visit or all-cause death&#xD;
&#xD;
        -  Cohort 2 (&lt;18 Years Old, Not Pregnant at Randomization)&#xD;
&#xD;
             -  To evaluate the safety and tolerability of REGN10933+REGN10987 compared to placebo&#xD;
&#xD;
             -  To further characterize the concentrations of REGN10933 and REGN10987 in serum over&#xD;
                time&#xD;
&#xD;
             -  To assess the immunogenicity of REGN10933 and REGN10987&#xD;
&#xD;
        -  Cohort 3 (Pregnant at Randomization)&#xD;
&#xD;
             -  To evaluate the safety and tolerability of REGN10933+REGN10987&#xD;
&#xD;
             -  To characterize the concentrations of REGN10933 and REGN10987 in serum over time&#xD;
&#xD;
             -  To assess the immunogenicity of REGN10933 and REGN10987&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 16, 2020</start_date>
  <completion_date type="Anticipated">August 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 10, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase 1/Phase 2/Phase 3</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with treatment-emergent serious adverse events (SAEs)</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Primary:&#xD;
Phase 1, Phase 3 (Cohort 2 and Cohort 3)&#xD;
Secondary:&#xD;
Phase 2, Phase 3 (Cohort 1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients with infusion-related reactions</measure>
    <time_frame>Through Day 4</time_frame>
    <description>Primary:&#xD;
Phase 1, Phase 3 (Cohort 2 and Cohort 3)&#xD;
Secondary:&#xD;
Phase 2, Phase 3 (Cohort 1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients with hypersensitivity reactions</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Primary:&#xD;
Phase 1, Phase 3 (Cohort 2 and Cohort 3)&#xD;
Secondary:&#xD;
Phase 2, Phase 3 (Cohort 1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time-weighted average change from baseline in viral load (log10 copies/mL), as measured by quantitative reverse transcription quantitative polymerase chain reaction (RT-qPCR) in nasopharyngeal (NP) swab samples</measure>
    <time_frame>Baseline up to Day 7</time_frame>
    <description>Primary:&#xD;
Phase 1, Phase 2&#xD;
Secondary:&#xD;
Phase 3 (Cohort 1), Phase 3 (Cohort 2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative incidence of patients with at least one (≥1) COVID-19 related medically attended visit or all-cause death</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Primary:&#xD;
Phase 3 (Cohort 1)&#xD;
Secondary:&#xD;
Phase 3 (Cohort 2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of REGN10933 in serum over time</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Primary:&#xD;
Phase 3 (Cohort 2 and Cohort 3)&#xD;
Secondary:&#xD;
Phase 1, Phase 2, Phase 3 (Cohort 1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of REGN10987 in serum over time</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Primary:&#xD;
Phase 3 (Cohort 2 and Cohort 3)&#xD;
Secondary:&#xD;
Phase 1, Phase 2, Phase 3 (Cohort 1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of anti-drug antibodies (ADA) to REGN10933</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Primary:&#xD;
Phase 3 (Cohort 2 and Cohort 3)&#xD;
Secondary:&#xD;
Phase 1, Phase 2, Phase 3 (Cohort 1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of ADA to REGN10987</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Primary:&#xD;
Phase 3 (Cohort 2 and Cohort 3)&#xD;
Secondary:&#xD;
Phase 1, Phase 2, Phase 3 (Cohort 1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of neutralizing antibody (NAb) to REGN10933</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Primary:&#xD;
Phase 3 (Cohort 2 and Cohort 3)&#xD;
Secondary:&#xD;
Phase 3 (Cohort 1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of NAb to REGN10987</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Primary:&#xD;
Phase 3 (Cohort 2 and Cohort 3)&#xD;
Secondary:&#xD;
Phase 3 (Cohort 1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time-weighted average change from baseline in viral load (log10 copies/mL), as measured by RT-qPCR in saliva samples</measure>
    <time_frame>Baseline up to Day 22</time_frame>
    <description>Phase 1 Only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-weighted average change from baseline in viral load (log10 copies/mL), as measured by RT-qPCR in nasal swab samples</measure>
    <time_frame>Baseline up to Day 22</time_frame>
    <description>Phase 1 Only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to negative RT-qPCR in all tested samples with no subsequent positive RT-qPCR in any tested samples</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 1 Only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to negative RT-qPCR in NP swabs with no subsequent positive RT-qPCR</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 2 Only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in viral load at each visit, as measured by RT-qPCR in NP swabs</measure>
    <time_frame>Baseline up to Day 29</time_frame>
    <description>Phase 1, Phase 2, Phase 3 (Cohort 1), Phase 3 (Cohort 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in viral load at each visit, as measured by RT-qPCR in saliva samples</measure>
    <time_frame>Baseline up to Day 29</time_frame>
    <description>Phase 1 Only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in viral load at each visit, as measured by RT-qPCR in nasal swabs</measure>
    <time_frame>Baseline up to Day 29</time_frame>
    <description>Phase 1 Only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of RT-qPCR results over time between different sample types (NP, nasal, and saliva)</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>Phase 1 Only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concordance of RT-qPCR results over time between different sample types (NP, nasal, and saliva)</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>Phase 1 Only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-weighted average change from baseline in viral load (log10 copies/mL) from day 1 to post-baseline study days</measure>
    <time_frame>Day 1 to Day 29</time_frame>
    <description>Phase 1, Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with ≥1 COVID-19 related medically-attended visit</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 1, Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with ≥2 COVID-19 related medically-attended visit</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 1, Phase 2, Phase 3 (Cohort 1), Phase 3 (Cohort 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of COVID-19 related medically-attended visits</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 1, Phase 2, Phase 3 (Cohort 1), Phase 3 (Cohort 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants admitted to a hospital due to COVID-19</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 1, Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with ≥1 outpatient or telemedicine visit due to COVID-19</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 1, Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of pharmacokinetic (PK) parameter: maximum serum concentration observed (Cmax) of REGN10933</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 1 Only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: maximum serum concentration observed (Cmax) of REGN10987</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 1 Only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: Cmax-to-dose ratio (Cmax/dose) of REGN10933</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 1 Only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: Cmax-to-dose ratio (Cmax/dose) of REGN10987</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 1 Only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: Time to Cmax (tmax) for REGN10933</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 1 Only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: Time to Cmax (tmax) for REGN10987</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 1 Only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: Area Under the Curve (AUC) computed from time zero to the time of the last positive concentration (AUClast) for REGN10933</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 1 Only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: AUC computed from time zero to the time of the last positive concentration (AUClast) for REGN10987</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 1 Only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with high viral load at each visit</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 2 Only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with viral loads below the limit of detection at each visit</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 2 Only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with viral loads below the lower limit of quantitation at each visit</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 2 Only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants admitted to an intensive care unit (ICU) due to COVID-19</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 2, Phase 3 (Cohort 1), Phase 3 (Cohort 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants requiring mechanical ventilation due to COVID-19</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 2, Phase 3 (Cohort 1), Phase 3 (Cohort 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of hospitalization due to COVID-19</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 2, Phase 3 (Cohort 1), Phase 3 (Cohort 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with all-cause mortality</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 2 Only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first onset of symptoms consistent with COVID-19 (asymptomatic cohort only)</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>Phase 2 Only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of symptoms consistent with COVID-19</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>Phase 2 Only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of participants with ≥1 COVID-19-related hospitalization, emergency room visit, or all-cause death</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 3 (Cohort 1), Phase 3 (Cohort 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with ≥1 COVID-19-related hospitalization, emergency room visit, or all-cause death</measure>
    <time_frame>Through day 29</time_frame>
    <description>Phase 3 (Cohort 1), Phase 3 (Cohort 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of participants with ≥1 COVID-19-related hospitalization or all-cause death</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 3 (Cohort 1), Phase 3 (Cohort 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with ≥1 COVID-19-related hospitalization or all-cause death</measure>
    <time_frame>Through day 29</time_frame>
    <description>Phase 3 (Cohort 1), Phase 3 (Cohort 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with ≥1 COVID-19-related medically-attended visit or all-cause death</measure>
    <time_frame>Through day 29</time_frame>
    <description>Phase 3 (Cohort 1), Phase 3 (Cohort 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with ≥1 COVID-19 related medically-attended visit by type of visit</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 3 (Cohort 1), Phase 3 (Cohort 2)&#xD;
Type of visit defined as hospitalization, emergency room visit, urgent care, physician's office visit, and/or telemedicine visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants requiring supplemental oxygen due to COVID-19</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 3 (Cohort 1), Phase 3 (Cohort 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to all-cause death</measure>
    <time_frame>Through Day 169</time_frame>
    <description>Phase 3 (Cohort 1), Phase 3 (Cohort 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause death</measure>
    <time_frame>By Day 29, Day 120, and Day 169</time_frame>
    <description>Phase 3 (Cohort 1), Phase 3 (Cohort 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral load over time in participants with COVID-19-related medically-attended visits</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 3 (Cohort 1), Phase 3 (Cohort 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral load over time in participants without COVID-19-related medically-attended visits</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 3 (Cohort 1), Phase 3 (Cohort 2)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">6420</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>REGN10933+REGN10987 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>REGN10933+REGN10987 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN10933+REGN10987 combination therapy</intervention_name>
    <description>Administered intravenously (IV) single dose</description>
    <arm_group_label>REGN10933+REGN10987 high dose</arm_group_label>
    <arm_group_label>REGN10933+REGN10987 low dose</arm_group_label>
    <other_name>REGN-COV2</other_name>
    <other_name>casirivimab</other_name>
    <other_name>imdevimab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo IV Single Dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Has SARS-CoV-2-positive diagnostic test (from a sample collected ≤72 hours prior to&#xD;
             randomization, using a validated SARS-CoV-2 antigen, RT-PCR, or other molecular&#xD;
             diagnostic assay, and an appropriate sample such as nasopharyngeal [NP], nasal,&#xD;
             oropharyngeal [OP], or saliva)&#xD;
&#xD;
          -  Has symptoms consistent with COVID-19, as determined by the investigator, with onset&#xD;
             ≤7 days before randomization&#xD;
&#xD;
          -  Maintains O2 saturation ≥93% on room air&#xD;
&#xD;
          -  Is able to understand and complete study-related questionnaires (patients aged ≥12&#xD;
             years only)&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Was admitted to a hospital for COVID-19 prior to randomization, or is hospitalized&#xD;
             (inpatient) for any reason at randomization&#xD;
&#xD;
          -  Has participated, or is participating, in a clinical research study evaluating&#xD;
             COVID-19 convalescent plasma, mAbs against SARS-CoV-2 (eg, bamlanivimab), or&#xD;
             intravenous immunoglobulin (IVIG) within 3 months or within 5 half-lives of the&#xD;
             investigational product (whichever is longer) prior to the screening visit&#xD;
&#xD;
          -  Prior, current, or planned future use of any of the following treatments: COVID-19&#xD;
             convalescent plasma, mAbs against SARS-CoV-2 (eg, bamlanivimab), IVIG (any&#xD;
             indication), systemic corticosteroids (any indication), or COVID-19 treatments&#xD;
             (authorized, approved, or investigational)&#xD;
&#xD;
          -  Prior use (prior to randomization), current use (at randomization) or planned use&#xD;
             (within 90 days of study drug administration or per current CDC recommendations, as&#xD;
             applicable) of any authorized or approved vaccine for SARS-CoV-2&#xD;
&#xD;
          -  Has participated, is participating or plans to participate in a clinical research&#xD;
             study evaluation any authorized, approved or investigational vaccine for SARS-CoV-2&#xD;
&#xD;
        NOTE: Other Protocol defined Inclusion/Exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Administrator</last_name>
    <phone>844-734-6643</phone>
    <email>clinicaltrials@regeneron.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Canoga Park</city>
        <state>California</state>
        <zip>91303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>La Palma</city>
        <state>California</state>
        <zip>90623</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site 1</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site 2</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site 3</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Montclair</city>
        <state>California</state>
        <zip>91763</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94127</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33487</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Fort Pierce</city>
        <state>Florida</state>
        <zip>34982</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Loxahatchee Groves</city>
        <state>Florida</state>
        <zip>33470</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33184</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <zip>33880</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Downers Grove</city>
        <state>Illinois</state>
        <zip>60515</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Ames</city>
        <state>Iowa</state>
        <zip>50010-3014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <zip>70072</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Ridgewood</city>
        <state>New Jersey</state>
        <zip>07450</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10451</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Jamaica</city>
        <state>New York</state>
        <zip>11432</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45409</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45432</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Clinton</city>
        <state>South Carolina</state>
        <zip>29325</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78413</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77055</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Pearland</city>
        <state>Texas</state>
        <zip>77584</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Red Oak</city>
        <state>Texas</state>
        <zip>75154</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>98201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Bucuresti</city>
        <zip>021105</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Romania</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>June 8, 2020</study_first_submitted>
  <study_first_submitted_qc>June 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2020</study_first_posted>
  <last_update_submitted>January 7, 2021</last_update_submitted>
  <last_update_submitted_qc>January 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronavirus disease 2019 (COVID-19)</keyword>
  <keyword>Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2)</keyword>
  <keyword>coronavirus</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., Food and Drug Administration (FDA), European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

